Pathway Partners
Pathway Partners is a Seoul-based venture capital firm that invests in growth-stage Korean bio/healthcare and technology companies, managing approximately 172.9 billion KRW across 22 funds and 18 portfolio companies with a focus on KOSDAQ technology-specialty IPO candidates.
- Company typePrivate
- Founded2022
- HeadquartersGangneung, South Korea
- Headcount—
- GTM typeB2B
- OfferingServices
What Pathway Partners does
Pathway Partners (패스웨이파트너스) is a South Korea-based venture capital firm headquartered in Gangnam, Seoul, that invests in growth-stage companies across the bio/healthcare and technology sectors. The firm operates through two legal entities — Pathway Partners LLC (유한회사 패스웨이파트너스) and Pathway Investment Inc. (패스웨이인베스트먼트 주식회사) — and manages approximately 172.9 billion KRW (~$130M USD) in assets under management across 22 funds and 18 portfolio companies, with three disclosed positions of 10 billion KRW or more in Telepix, GeneEDIT, and Galux.
The firm's core differentiator is a proprietary technical evaluation framework used to assess and prepare candidates for technology-specialty IPOs (기술특례상장) on KOSDAQ, an approach grounded in CEO Lee Sang-jin's prior experience as CFO of Olix and Viewno — both of which completed such listings. The firm runs a multi-track due diligence process and operates a network of more than 45 domestic and international investment firms for deal sourcing and syndication, evidenced by recent co-investments with JB Investment (Amogy, 50 billion KRW, July 2025) and Loftic Investment (first blind fund of 117 billion KRW, December 2025). The portfolio spans bio/healthcare, climate technology, and deep tech, with non-capital services such as a financial advisory MOU with Samjung KPMG extending the value proposition beyond capital deployment.
Revenue mechanics are typical of a Korean growth-stage VC: management fees on committed capital (generally 1.5–2.0% in market practice) and carried interest on realized exits. Specific revenue, fee, or carry figures are not publicly disclosed. The firm serves Korean institutional LPs (disclosed backers include Hana Securities, UnidBTPlus, and Donggubio) and the founders and management teams of its 18 portfolio companies, with the value proposition increasingly anchored on IPO-readiness support rather than capital alone.
Pathway Partners firmographics
Firmographics- Name
- Pathway Partners
- Legal name
- 유한회사 패스웨이파트너스 / 패스웨이인베스트먼트 주식회사
- Website
- https://pathwaygroup.co.kr
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Short description
- Pathway Partners is a Seoul-based venture capital firm that invests in growth-stage Korean bio/healthcare and technology companies, managing approximately 172.9 billion KRW across 22 funds and 18 portfolio companies with a focus on KOSDAQ technology-specialty IPO candidates.
- Ownership category
- akta.pro rank
Pathway Partners industry classification
Industry- Product category
- Venture Capital Investment Services
- NAICS
- Funds, Trusts, and Other Financial Vehicles (525)
- SIC
- Investment Advice (6282), Investors, Nec (6799)
- akta.pro primary industry
- Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)
Keywords
Where Pathway Partners is headquartered
LocationHeadquarters
- HQ city
- Gangneung
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
Pathway Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Management Fees: VC/PE management fees collected from fund operations. The firm operates 22 funds including project funds, blind funds, and Co-GP structures, generating recurring management fee income.
- Carried Interest (성과의 보상): Performance-based carried interest from successful portfolio company exits through IPO or M&A. The firm targets listing or strategic sale as the primary exit path for invested companies.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Pathway Partners product offering
Product offeringCore offering
Pathway Partners is a Korean venture capital firm that invests growth-stage equity capital into bio/healthcare and technology companies (Series B and beyond) and provides active post-investment strategic support including ownership structure design, organizational restructuring, IPO and M&A preparation, and Korea Exchange technology-specialty listing (기술성평가) advisory. The firm operates 22 funds, including direct equity vehicles, a 117 billion KRW Co-GP blind fund with Loftic Investment, and project funds with co-investors such as JB Investment.
Product overview
Pathway Partners is a Korean venture capital firm that operates as a single unified investment services platform rather than a multi-module product suite. The firm specializes in bio/healthcare and technology sector investments, offering strategic financial partnership to startups. Related entities include Pathway Investment (패스웨이인베스트먼트), which focuses on pre-IPO investments, and manages funds such as the Pathway Loftlink Bio Healthcare Fund 1st (패스웨이로프티록바이오헬스케어조합1호). The firm provides investment services, IPO preparation support, technology evaluation, and M&A advisory to portfolio companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Pathway Partners Investment Services Venture capital and investment services specializing in bio/healthcare and technology growth-stage companies, providing strategic partnership, ownership structure design, organizational restructuring, IPO/M&A preparation, and Korea Exchange technology-specialty listing evaluation (기술성평가) support to portfolio companies.
- PathwayLofticBioHealthcareFund No.1 (Co-GP Blind Fund) 117 billion KRW Co-General Partner blind pool fund co-managed with Loftic Investment, targeting bio/healthcare growth-stage companies with pre-identified investment targets; LPs include Hana Securities and UnidBTPlus.
- Amogy Project Fund (with JB Investment) 50 billion KRW joint project fund with JB Investment for acquisition of preferred shares in Amogy, an ammonia-based decarbonization energy solutions company, with UnidBTPlus (KOSPI-listed) as anchor LP.
- Bio/Healthcare Growth-Stage Direct Equity Investment Program Direct equity investment program targeting bio/healthcare growth-stage companies (Series B and beyond) with active post-investment support including ownership structure design, organizational restructuring, and listing/M&A preparation.
Quantifiable outcome
- 18 companies invested in; 22 funds operated; cumulative AUM of approximately 1,729 billion KRW
- +2 more outcomes
Companies that use Pathway Partners
Customer profileSegments2 records
Ideal customer profiles2 records
Pathway Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Pathway Partners partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Samjung KPMG (삼정KPMG)corePathway Partners signed an MOU with Samjung KPMG for strengthened bio/healthcare financial advisory capabilities. Samjung KPMG's valuation and due diligence operations will involve Pathway Partners' specialized personnel to strengthen industry expertise. In return, Samjung KPMG will provide M&A advisory support for portfolio companies identified by Pathway Partners. This partnership addresses the challenge of evaluating non-financial factors in drug development portfolios and enables more precise industry-specific valuation for bio/healthcare investments.
Scale indicators8 records
Recent moves6 records
Expansion highlights4 records
Pathway Partners competitors and assessment
Company assessmentBroad incumbents
- KDB Capital: Korean state-backed investment company (KDB Group) deploying capital across VC and growth-stage mandates, including bio/healthcare, offering a comparable institutional LP/GP dynamic.
- KB Investment: Korean VC/PE arm of KB Financial Group, operating broadly across growth and buyout stages with overlapping bio/healthcare exposure but at a much larger and more diversified scale.
- Mirae Asset Venture Investment: Korean venture investment arm of Mirae Asset Financial Group, providing broader diversification across stages and sectors with overlap in tech and bio investing.
- IMM Investment: Large Korean private equity and venture investor with broad sector mandates, providing a benchmark for incumbent Korean PE/VCs that occasionally overlap with Pathway's growth-stage tech/bio investing.
Emerging players
- Smilegate Investment: Korean corporate-affiliated VC focused on technology and deep tech investments, including select bio exposure, comparable in scale and active value-add style to Pathway Partners.
Direct peers
- LB Investment: Korean mid-market PE/VC investing in growth-stage technology and life sciences companies with active value-up support, comparable to Pathway in stage, sector focus, and ticket size.
- Atinum Investment: Korean venture capital firm investing in growth-stage tech and bio/healthcare companies with active post-investment support, closely mirroring Pathway Partners' mandate and deal stage focus.
- Korea Investment Partners: Established Korean PE/VC firm with deep coverage of growth-stage technology and bio/healthcare, where CEO Lee Sang-jin previously led the PE investment team, providing a directly comparable operating model.
- TS Investment: Korean growth-stage VC with bio/tech focus and KOSDAQ pre-IPO orientation, pursuing a similar strategy of supporting companies through tech-specialty listings.
- Solid Investment: Korean growth-stage VC focused on bio and technology sectors, with comparable portfolio construction (pre-IPO, KOSDAQ tech-special listings) and similar fund structures to Pathway Partners.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Pathway Partners social profiles
Digital presencePathway Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pathway Partners leadership team
Management profileNumber of profiles
Profiles3 records
Pathway Partners subsidiaries and ownership
Company hierarchySubsidiaries1 record
Pathway Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pathway Partners M&A and investment
M&A and investmentM&A
Investments7 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pathway Partners
What does Pathway Partners do?
Pathway Partners is a Korean venture capital firm that invests growth-stage equity capital into bio/healthcare and technology companies (Series B and beyond) and provides active post-investment strategic support including ownership structure design, organizational restructuring, IPO and M&A preparation, and Korea Exchange technology-specialty listing (기술성평가) advisory. The firm operates 22 funds, including direct equity vehicles, a 117 billion KRW Co-GP blind fund with Loftic Investment, and project funds with co-investors such as JB Investment.
Is Pathway Partners a public or private company?
Pathway Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Pathway Partners founded?
Pathway Partners was founded in 2022.
Where is Pathway Partners based?
Pathway Partners is headquartered in Gangneung, South Korea, in the Asia region.
How does Pathway Partners make money?
Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest (성과의 보상).
Who are Pathway Partners's main competitors?
Broad incumbents on record are KDB Capital, KB Investment, Mirae Asset Venture Investment and IMM Investment. Smilegate Investment is listed as an emerging player. Direct peers are LB Investment, Atinum Investment, Korea Investment Partners, TS Investment and Solid Investment.
Does Pathway Partners have an API?
No public API is recorded for Pathway Partners.
What industry is Pathway Partners in?
Pathway Partners's product category is Venture Capital Investment Services. Its primary akta.pro industry code is FSANAAAJ, Venture Capital Fund-of-Funds / Multi-Manager Platforms. Its NAICS code is 525 and its SIC code is 6282.